Lapatinib Hertab
| Product/Composition | Lapatinib Tablets |
|---|---|
| Strength | 250mg |
| Form | Tablet |
| Production Capacity | 10 Million Tablets/Month |
| Packaging | 10 X 10 Tablets / Box |
| Therapeutic use | HER2-Positive Breast Cancer |
| Package Insert/Leaflet | Available upon request |
| Brand Name | Hertab |
Hertab contains Lapatinib, an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. Lapatinib inhibits the intracellular tyrosine kinase activity of HER2 (ErbB2) and EGFR (ErbB1), interfering with signaling pathways involved in the growth and survival of certain cancer cells.
Lapatinib is primarily used in combination with other anticancer medicines for selected patients with HER2-positive advanced or metastatic breast cancer. It is a prescription medicine and should be used under the supervision of a qualified oncologist.
What is Lapatinib?
Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor. It blocks signaling from HER2 and EGFR receptors, which can reduce pathways involved in tumor-cell proliferation and survival.
Lapatinib is used in selected treatment regimens for HER2-positive advanced or metastatic breast cancer, including combination treatment with medicines such as capecitabine or trastuzumab where clinically appropriate.
Benefits and Uses of Hertab
Hertab (Lapatinib) may be prescribed for:
- Treatment of selected HER2-positive advanced or metastatic breast cancer
- Use in combination with capecitabine in appropriate treatment settings
- Use in combination with trastuzumab for selected patients
- Inhibition of HER2-mediated cancer-cell signaling
- Targeted treatment based on the molecular characteristics of the tumor
The appropriate treatment regimen depends on HER2 status, previous treatment, disease progression, and the patient’s clinical condition.
Dosage Guidelines
The dosage of Lapatinib depends on the specific treatment regimen and combination medicine being used.
- Take Hertab exactly as prescribed by the treating oncologist.
- Lapatinib is administered orally, generally once daily in approved breast-cancer regimens.
- Tablets should be swallowed whole with water.
- Lapatinib should generally be taken at least one hour before or at least one hour after food.
- Do not change the prescribed dose without medical advice.
- If a dose is missed, follow the instructions provided by the treating healthcare professional rather than taking an additional dose.
Healthcare professionals may monitor liver function and cardiac function during treatment.
Wholesale & Supply
Onco India International can support wholesale and bulk pharmaceutical supply of Hertab (Lapatinib) for eligible markets and pharmaceutical procurement requirements.
Bulk supply may be suitable for:
- Pharmaceutical distributors
- Hospitals and healthcare institutions
- Oncology distributors
- International pharmaceutical buyers
- Licensed importers and exporters
- Healthcare procurement organizations
Packaging, minimum order quantities, documentation, and availability may vary according to market requirements.
Buying Lapatinib Online
When sourcing Hertab or other Lapatinib products, buyers should verify the strength, dosage form, manufacturer, batch information, packaging, and applicable quality documentation.
Lapatinib is a prescription anticancer medicine. Pharmaceutical products should be obtained through authorized and appropriately licensed suppliers and used under qualified medical supervision.
Reviews
Individual responses to Lapatinib may vary depending on HER2 status, cancer stage, previous therapies, combination treatment, and patient-specific factors.
For pharmaceutical procurement, important considerations include product quality, manufacturing standards, documentation, packaging integrity, and supply reliability.
Quality Assurance
Quality assurance is essential for targeted oncology medicines such as Lapatinib. Products should be manufactured, tested, packaged, and stored according to applicable pharmaceutical quality and regulatory requirements.
Relevant documentation, including available product specifications, certificates, batch information, and package inserts, can be requested where applicable.
Frequently Asked Questions
What is Hertab used for?
Hertab contains Lapatinib and is used in selected treatment regimens for HER2-positive advanced or metastatic breast cancer.
What type of medicine is Lapatinib?
Lapatinib is a tyrosine kinase inhibitor (TKI) that targets HER2 and EGFR signaling.
How does Lapatinib work?
Lapatinib inhibits the intracellular tyrosine kinase activity of HER2 and EGFR, disrupting signaling pathways that can promote cancer-cell growth and survival.
Is Lapatinib used for HER2-positive breast cancer?
Yes. Lapatinib is used in selected patients with HER2-positive advanced or metastatic breast cancer, generally as part of a combination treatment regimen.
How is Lapatinib administered?
Lapatinib is taken orally, generally once daily in approved breast-cancer regimens. The exact dose depends on the treatment combination.
Should Lapatinib be taken with food?
Lapatinib is generally taken on an empty stomach, at least one hour before or at least one hour after food. Patients should follow the specific product instructions.
What are common side effects of Lapatinib?
Possible adverse effects include diarrhea, nausea, vomiting, rash, hand-foot syndrome, and fatigue. Changes in liver function can also occur.
Can Lapatinib affect the heart?
Yes. Lapatinib can affect cardiac function in some patients. Appropriate cardiac monitoring may be performed when clinically indicated.
Can Lapatinib affect the liver?
Yes. Lapatinib can cause liver injury, including serious hepatotoxicity in rare cases. Liver-function monitoring may therefore be required.
Conclusion
Hertab (Lapatinib) is an oral targeted anticancer medicine that inhibits HER2 and EGFR tyrosine kinase signaling. It is used in selected treatment regimens for HER2-positive advanced or metastatic breast cancer.
Because treatment selection, combination therapy, and monitoring depend on the patient’s disease characteristics and previous treatment, Lapatinib should be prescribed and monitored by a qualified oncology professional.

